Part 1: background, methodology, and clinical adoption of pharmacogenetics.

@article{Deenen2011Part1B,
  title={Part 1: background, methodology, and clinical adoption of pharmacogenetics.},
  author={Maarten J. Deenen and Annemieke Cats and Jos H. Beijnen and Jan H. M. Schellens},
  journal={The oncologist},
  year={2011},
  volume={16 6},
  pages={811-9}
}
Equivalent drug doses may lead to wide interpatient variability with regard to drug response, reflected by differences in drug activity and normal tissue toxicity. A major factor responsible for this variability is variation among patients in their genetic constitution. Genetic polymorphism may affect the activity of proteins encoded, which in turn may lead to changes in the pharmacokinetic and pharmacodynamic behavior of a drug, observed as differences in drug transport, drug metabolism, and… CONTINUE READING

From This Paper

Topics from this paper.